Effect of aspirin treatment duration on clinical outcomes in acute coronary syndrome patients with early aspirin discontinuation and received P2Y12 inhibitor monotherapy

被引：0
|
作者：
Chen, P. -W. [1 ]
Ho, M. -Y. [2 ]
Feng, W. -H. [3 ]
Su, C. -H. [4 ]
Huang, S. -W. [4 ]
Cheng, C. -W. [5 ]
Yeh, H. -I. [5 ]
Chen, C. -P. [6 ]
Huang, W. -C. [7 ]
Fang, C. -C. [8 ]
Lin, H. -W. [1 ]
Lin, S. -H. [1 ]
Hsieh, I. -C. [2 ]
Li, Y. -H. [1 ]
机构：
[1] Natl Cheng Kung Univ Hosp, Tainan, Taiwan
[2] Chang Gung Univ, Chang Gung Mem Hosp, Coll Med, taoyuan, Taiwan
[3] Kaohsiung Med Univ Hosp, Kaohsiung, Taiwan
[4] Chung Shan Med Univ Hosp, Taichung, Taiwan
[5] Mackay Mem Hosp, Taipei, Taiwan
[6] Changhua Christian Hosp, Changhua, Taiwan
[7] Kaohsiung Vet Gen Hosp, Kaohsiung, Taiwan
[8] Tainan Municipal Hosp, Tainan, Taiwan
来源：
EUROPEAN HEART JOURNAL | 2021年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1208 / 1208
页数：1
相关论文
共 50 条
  • [41] What Are Optimal P2Y12 Inhibitor and Schedule of Administration in Patients With Acute Coronary Syndrome?
    Cohen, Michael V.
    Downey, James M.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2020, 25 (02) : 121 - 130
  • [42] The impact of in-hospital P2Y12 inhibitor switch in patients with acute coronary syndrome
    Gajanana, Deepakraj
    Weintraub, William S.
    Kolm, Paul
    Rogers, Toby
    Iantorno, Micaela
    Buchanan, Kyle D.
    Ben-Dor, Itsik
    Pichard, Augusto D.
    Satler, Lowell F.
    Thourani, Vinod H.
    Torguson, Rebecca
    Okubagzi, Petros G.
    Waksman, Ron
    CARDIOVASCULAR REVASCULARIZATION MEDICINE, 2018, 19 (08) : 912 - 916
  • [43] TIMELY LIVER TRANSPLANT IN CIRRHOTIC PATIENTS AFTER CORONARY STENTING AND EARLY DISCONTINUATION OF P2Y12 INHIBITOR
    Saracco, Margherita
    Calleri, Alberto
    Manuli, Chiara
    Lavezzo, Bruna
    Tandoi, Francesco
    Giorgi, Mauro
    Ottobrelli, Antonio
    Panio, Angelo
    Balagna, Roberto
    Romagnoli, Renato
    Martini, Silvia
    HEPATOLOGY, 2022, 76 : S455 - S456
  • [44] P2Y12 Inhibitor Monotherapy After Short-Term Dual Antiplatelet Therapy in Acute Coronary Syndrome
    Singh, Sahib
    Garg, Aakash
    Tantry, Udaya S.
    Bliden, Kevin
    Abbott, J. Dawn
    Gurbel, Paul A.
    AMERICAN JOURNAL OF CARDIOLOGY, 2024, 224 : 1 - 8
  • [45] Reversible P2Y12 inhibitor versus irreversible P2Y12 inhibitor in ACS patients undergoing PCI (the acute coronary syndrome israeli survey (ACSIS)
    Eliaz, R.
    Mengesha, B.
    Ovdat, T.
    Iakobishvili, Z.
    Hasdai, D.
    Kheifets, M.
    Klempfner, R.
    Beigel, R.
    Kalmanovich, E.
    Alcalai, R.
    Levi, A.
    EUROPEAN HEART JOURNAL, 2021, 42 : 1414 - 1414
  • [46] P2Y12 INHIBITOR ADHERENCE TRAJECTORIES IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
    Turgeon, Ricky D.
    Koshman, Sheri
    Dong, Yuan
    Graham, Michelle
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 16 - 16
  • [47] P2Y12 inhibitors for the treatment of acute coronary syndrome patients undergoing percutaneous coronary intervention: current understanding and outcomes
    Alexopoulos, Dimitrios
    Varlamos, Charalampos
    Mpahara, Aikaterini
    Lianos, Ioannis
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2019, 17 (10) : 717 - 727
  • [48] Long-Term P2Y12 Inhibitor or Aspirin as Single Antiplatelet Therapy in Patients With Previous Percutaneous Coronary Intervention
    Capodanno, Davide
    Angiolillo, Dominick J.
    CIRCULATION, 2023, 147 (02) : 118 - 121
  • [49] The efficacy and safety of P2Y12 inhibitor monotherapy in patients after percutaneous coronary intervention
    Luo, Liman
    Fu, Menglu
    Li, Yuanyuan
    Chen, Zhihui
    Yu, Jing
    Luo, Jinlan
    Hu, Shuiqing
    Tu, Ling
    Xu, Xizhen
    CLINICAL CARDIOLOGY, 2020, 43 (03) : 235 - 241
  • [50] Trajectories of P2Y12 inhibitor adherence in patients with acute coronary syndromes
    Moon, Jungyeon
    Ozaki, Aya F.
    Chong, Alice
    Sud, Maneesh
    Fang, Jiming
    Austin, Peter C.
    Ko, Dennis T.
    Jackevicius, Cynthia A.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 (01)
12345